Acentrus Specialty (Acentrus), a national network of health systems and hospitals committed to providing specialty pharmacy care for their patients, finalized an agreement with Puma Biotechnology to provide qualified Acentrus clients access to NERLYNX® (neratinib), a limited distribution drug.
NERLYNX is intended for adults with HER2+ breast cancer who have received 2 or more anti-HER2 therapies for metastatic breast cancer. NERLYNX is taken with a medicine called capecitabine to help prevent metastatic breast cancer from progressing any further.
Participation in Acentrus is open to hospital organizations of all sizes, types and affiliations. There is no cost for an organization to join the Acentrus network, which provides more than 100 health systems and hospitals with the following benefits:
- Access to difficult-to-obtain specialty medications
- Data management
- Collaboration with health system peers dedicated to sharing best practices
- Portfolio of other services
Earlier this year, Acentrus Specialty and Maxor National Pharmacy Services signed an agreement to provide health system clients contract and backup pharmacy services.
Acentrus Specialty is a separate Apexus offering that is not a part of the 340B Prime Vendor Program or otherwise associated with the Prime Vendor Agreement between HRSA and Apexus.
In addition to serving as the HRSA-designated Prime Vendor for the 340B Drug Pricing Program, Apexus offers professional training and validation through its Advanced 340B Operations Certificate Program, and provides a health system solution for specialty pharmacy through Acentrus Specialty.
Apexus is a subsidiary of Vizient, the largest member-driven, health care performance improvement company in the country.
Takeaway: Acentrus Specialty’s hospital and health system network has surpassed 100 members